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Abstract: A proportion of young people with Down syndrome (DS) experience unexplained re-
gression that severely impacts on their daily lives. While this condition has been recognised by
clinicians, there is a limited understanding of causation and an inconsistent approach to diagnosis
and treatment. Varied symptomology and little knowledge of the cause of this regression have
impacted on clinician’s ability to prevent or manage this condition. The purpose of this review
was to examine the current evidence surrounding unexplained regression in adolescents and young
adults, and to establish patterns that may be of use to clinicians, as well as raising awareness of this
condition. Four areas were specifically reviewed, (1) terminology used to refer to this condition,
(2) the symptoms reported, (3) potential trigger events and, (4) treatments and prognosis. A variety
of terminology is used for this condition, which has constrained past attempts to identify patterns.
An extensive number of symptoms were reported, however sleep impairment, loss of language and
distinct changes in personality and behaviour, such as disinterest and withdrawal, were among the
most frequently seen. Life events that were tentatively associated with the onset of a regressive period
included a significant change in environmental circumstances or a transition, such as moving home
or leaving school. Prognosis for this condition is relatively positive with the majority of individuals
making at least a partial recovery. However, few patients were found to make a full recovery to their
previous level of functioning and serious adverse effects could persist in those who have made a
partial recovery. This is an under-researched condition with significant impacts on people with DS
and their families. There are no established treatments for this condition and there is relatively little
recognition in the research community. Further studies that focus on the prevention and treatment of
this condition with controlled treatment trials are needed.
Keywords: Down syndrome; early regression; idiopathic regression
1. Introduction
Down syndrome (DS) is the most common syndrome associated with the presence
of an intellectual disability, affecting approximately 3.3–6.7 per 10,000 individuals world-
wide [1]. Family members and clinicians have noted the occurrence of cognitive deteriora-
tion and skills loss specifically in a small portion of adolescents and young adults, often
without a distinct cause. This unexplained regression is profound and has a serious impact
on both the individual and their families. A great number of different terms have been used
in the diagnosis of this regression. Recently, “Down syndrome disintegrative disorder”
(DSDD) and idiopathic regression in DS (IRDS) have been used more frequently. The latter
term, IRDS, will be used in this review.
Despite the occurrence of IRDS being well-recognised by clinicians as affecting a
minority of young people with DS, research in this area is sparse [2–4]. Characteristically,
the symptoms and signs of this condition include significant impacts on the person’s
cognitive and language functioning, their ability to perform daily tasks, a considerable loss
of previously acquired daily skills, mild to severe alterations in personality and behaviour
Brain Sci. 2021, 11, 1197. https://doi.org/10.3390/brainsci11091197 https://www.mdpi.com/journal/brainsci
Brain Sci. 2021, 11, 1197 2 of 21
and the onset of social withdrawal. IRDS is described by families as having a profound
effect on the abilities of the person with DS to live as they have previously been able to.
This has a knock-on effect on members of their family and other carers, and often results in
the need for major changes in their living situation and care needs.
This condition typically occurs in early adolescence to young adulthood and there are
currently no confirmed causes or triggers and no consistent treatment pathways. In IRDS,
presenting symptoms sometimes overlap with features of autism and dementia, however
the age profiles for these other conditions are different. Autism spectrum disorder (ASD)
presents in early childhood and a diagnosis of Alzheimer’s disease (AD), based on the
onset of clinical symptoms, is most commonly made in the fifth decade. With dementia
in people with DS, the neuropathological hallmarks are often seen earlier, (around the
40s) [5,6], but a clinical diagnosis of dementia is not usually made until the patient is in
their 50s. This high risk of AD for people with DS is customarily theorised to be linked to
the triplication of chromosome 21 and therefore the presence of three copies of the amyloid
precursor protein gene, and the resultant lifelong overproduction of the beta-amyloid
(Aβ) protein [7]. Despite the high risk of AD specific to people with DS, there is minimal
evidence to suggest that AD presentation occurs at the age when individuals are most likely
to be affected by IRDS. Furthermore, with IRDS there is often stabilisation and/or recovery
of symptoms, as opposed to when it is dementia where progression with no recovery is
what is to be expected. It is generally accepted that IRDS symptoms are not a consequence
of either the above conditions and should be considered as separate.
A recent paper by Santoro et al. [4] reported the findings from a retrospective chart
review of 35 people with DS and regression. Using a checklist of symptoms were classified
into five core “features” including: (a) adaptive functions, (b) functional and procedural
memory deficits (c) motor control impairment; (d) catatonia and; (e) disturbances associated
with mental ill-health. The strengths of this study included the analysis of symptomatology
in a group of people with DS, who experts had agreed had unexplained regression, and
the use of an agreed checklist of symptoms. Most importantly, and uniquely in this
field, this study compared symptomatology and test scores of patients with an aged-
matched group of people with DS with no evidence of IRDS, thus helping to validate the
recorded clinical observations. The authors do not report the temporal sequence of specific
clinical symptoms. However, the majority of symptoms identified in those with IRDS were
not experienced in the healthy controls, the exceptions to this being the mental health
categorisations and externalising behaviours (hyperactive, irritable, disruptive, agitated)
where there were no significant differences between IRDS and DS groups.
During the preparation of this systematic review another review paper was published
summarising reported studies of regression in people with DS [8]. This paper identified
language regression, mood disturbance and new onset insomnia as being particularly
common features. They proposed that there were two potential causative mechanisms,
one relating to immune dysfunction, and the other being stress related. Clinically, it
was argued that an extensive work-up is still required to identify possible rare causes of
regression, including the co-occurrence of other genetic disorders, such as Lesch Nyhan
syndrome, in which a similar regression occurs but much earlier in life. Our systematic
review complements this paper, drawing in greater depth on case studies as well as
reports on case series of IRDS in adolescents and young adults with DS, and examining
how symptoms cluster and co-present. Our primary objective, by extending the work
undertaken by Rosso et al. [8], was to help improve diagnosis by heightening awareness of
this condition among clinicians and providing further details of the main characteristics
and their relationships to each other. We also reflect on terminology, clinical practice and
possible causation.
Our review has focussed on observations from case studies and research on IRDS
in adolescents and young adults with DS. The specific aims were to identify patterns of
(a) symptomology, (b) potential trigger events and, (c) prognosis, treatments and outcomes.
Possible causation will be considered to highlight the need for treatment trials for this
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condition based on the understanding of causal mechanisms. In addition to raising aware-
ness of the condition we highlight the importance and necessity of further research of
this condition.
2. Methodology
2.1. Identification of Articles
This systematic review was conducted according to the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) statement [9] and was accepted
to the Prospero platform (registration CRD42019156614). PubMed and Scopus databases
were searched in November 2019 using the following search strategy: [“regression”] and
[“Down* syndrome”]. Publication date and article language were not restricted; however,
a filter was applied restricting articles to those involving human participants only. PubMed
search fields included title and abstract, and in Scopus, title, abstract and keywords were
included. As this systematic review did not contain independent research, ethical approval
was not required, and consent procedures were not applicable.
2.2. Inclusion Criteria
Articles were examined for relevance by manually screening of the titles, abstracts
and the keywords included. References of the retained articles were studied for further
relevant papers, which were then examined against the same criteria.
Inclusion criteria were as follows:
• Research article involving at least one individual with DS.
• Age of patient under 35 years.
• Evidence of at least one regressive period that included changes to cognition, func-
tioning and/or behaviour and personality.
• Regression identified did not progress to a clinical diagnosis of AD.
Cases with a co-diagnosis of pre-morbid autism in DS and early regression due to
autism were not included. The inclusion of an upper age restriction was necessary in order
to minimise the number of persons with DS whose symptoms may have been caused by
the onset of AD. Furthermore, any individual cases included in papers who fell outside of
this age limit were excluded from the review. Those with pre-existing features of catatonia
were not excluded from this review due to the high incidence of presentation as part of
IRDS. No other restrictions, such as language or year of publication, were included.
2.3. Data Collection Process
Data sought from the articles obtained included (a) terminology used to describe
the condition (e.g., regression, catatonia), (b) symptomology (e.g., change in mental state,
general mental functioning, level of living skills, sleep, appetite), (c) noted trigger events
(e.g., life events such as bereavement, physical illness), (d) treatments prescribed (medica-
tion, psychological interventions, etc.) and (e) outcomes. For case studies this information
was extracted on an individual basis and for cohort studies at a group level in accordance
with the style of the individual article. Where possible this information was collated,
otherwise two groups were considered for analysis (Group A—case study participants,
Group B—cohort study participants).
3. Methodology
3.1. Article Search Results
A total of 1938 articles were identified from the initial search. Due to the search term
“regression” without further specification, our search was deliberately over-inclusive. It
was felt that due to the inconsistencies of terminology and labelling used in referring to
this condition this was a necessary step in order to capture as many related articles as
possible and to achieve our aim of collating the various terminologies used. Title, keyword
and abstract review eliminated the vast majority of articles, leaving 57 articles for full-text
review. A further four articles were sourced from references and full-text screening with
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the same inclusion criteria applied to these articles was completed. Ultimately 14 articles
were retained. A full-text version could not be sourced for three articles, and two others
were sourced at a later date, leaving a final total of 13 articles for inclusion in this review.
The search pathway is shown in Figure 1 and the final included articles are summarised in
Table 1.
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Myers and Pueschel (1995) [10] 8 8 4:4 Range 21–44 years
Capone, Aidikoff and Goyal (2011) [11] 0 33 14:19 Range 13–35 yearsMean 22 years
Akahoshi et al. (2012) [12] 12 12 6:6 Range 13–29 years
Stein et al. (2013) [13] 1 1 Female 13 years
Capone et al. (2013) [14] 0 28 14:14 Male mean 21.8 yearsFemale mean 20.3 years
Dykens et al. (2015) [3] 1 49 49% male Range 13–29 years
Ghaziuddin, Nassiri and Miles (2015) [15] 4 4 2:2 Range 14– 8 years
Jacobs et al. (2016) [16] 1 1 Male 19 years
Tamasaki et al. (2016) [17] 1 1 Male 15 years
Mircher et al. (2017) [18] 0 30 20:10 Range 12–30 years
Car ale et al. (2018) [19] 4 4 3:1 Range 17–25 ye
Santoro et al. (2019) [4] 0 35 53% female 9–34 years
Miles et al. (2020) [20] 7 0 6:1 18–33 years
3.2. Additional Comments and Exclusions
Articles where the age range of the participants extended outside of our 35-year upper
age limit underwent an additional level of scrutiny. In research articles where cases could
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not be distinguished from each other, these were excluded, however in case studies or
where this information was available, only the individual cases that did not meet our
inclusion criteria were excluded from that particular review. Further exclusions included
specified autistic regression and progression to AD. Two individual cases were excluded
from this review based on the above criteria respectively. A ten-year-old female [12] and
a 44-year-old male [10]. Table 1 reflects the number of participants after these additional
exclusions. Case-control studies identified that did not distinguish between young children
and adolescents could not be included in the review [4,21,22].
4. Results
4.1. Patient Demographics
The total number of people with DS included in the subsequent analyses was 186.
Case report data were available for 39 patients with DS, these formed Group A. Group B
represented the 147 patients without individual case study reports, the cohort group. One
hundred patients (53.7%) were female and 86 (46.2%) male. The mean age of onset was
20.97 years. However, this statistic is not truly representative for two reasons. First, the
cohort studies provided only mean age and age range, therefore individual ages could
not be entered into this analysis. Secondly, differences between age of onset and age
at presentation were not always specified in the case studies. In comparison to other
studies that have looked at average age of onset, our estimate may be considered high;
Santoro et al., [4] for example identified 17.5 years as the typical age that regressive
symptoms first appear.
4.2. Descriptive Terminology
There were considerable problems with the search strategies used in this systematic
review. One of which was deliberate. The use of the word “regression” in the search terms
led to massive overlap with usage in statistical terminology. This led to many retrieved
articles being unrelated to the review topic. It was however necessary to include this term
in order to capture all relevant articles.
One of our primary intentions of this review was to evaluate the wide variety of
terminologies that are used to describe and diagnose this condition (see Table 2). Analysis of
the terms used across the 13 papers entered in this review revealed that five different terms
including the word “regression” were used, as well as a further 10 different descriptors not
including the word regression. These terminologies have been grouped and the frequency
of their appearance is noted in Table 2. Multiple terms were often used in single papers,
presumably reflecting the uncertainty and inconsistency in this area.
Table 2. List of the terminology used to describe the group of patients within the article. Articles may have referenced
multiple terminologies.
Regression Related Terminology Times Used Disorder Related Terminology Times Used Function RelatedTerminology Times Used




Disorder 2 Clinical deterioration 1
Cognitive regression 1 New-onset mood disorder 1 Functional decline 1
Unexplained regression 2 Acute neuropsychiatric disorders 1
Rapid regression 2 Depression/major depression 3
Acute regression 2
Total 10 Total 8 Total 3
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4.3. Symptom Severity and Diversity
The majority of studies included in this review provided detailed information regard-
ing patient symptoms. In our analysis we first assessed the qualitative data from the case
studies (Group A). Our aim was to establish the most commonly reported symptoms from
Group A, and then supplement these with the data from Group B. Additional symptoms
that occurred in <10% of case studies reviewed were not included in this analysis or in
Figure 2. Some Group B data could not be included as no symptoms were recorded [3]. In
addition, symptoms were frequently reported differently between studies, for example,
“catatonia” and “slowness of movement” were grouped as one category in one study [18],
and “depression” and “compulsions” were grouped together in another [4]. To avoid miss-
ing the subtleties of these symptoms it was decided that, in these circumstances, patients
should be recorded as having both symptoms.
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Figure 2. Number of cases in Group A (case stu y patients) an roup B (cohort study patients) displaying most prevalent
symptoms of IRDS.
From the results f l sis, 15 independent symptoms w re identified that were
present in more than 10 atients. Some symptoms w re reported heavily in
individual studies a t re in others. For example, abulia was inclu ed in
only two papers [4,12], r inently in both. In Akahoshi et al. [12] 10 of the
12 of patients include i as showing signs of abuli and in Sant ro et al. [4]
28 of 35 patients were recorded as having a symptom under the heading of “motor control”,
which included the features of abulia, avolition, and mutism.
Figure 2 shows the number of cases in each of the two groups of patients reported as
having a particular symptom. Sleep disorders were the most commonly reported symptom
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in both groups and across all patients. Other highly occurring symptoms included language
decline, disinterest/withdrawal, depression and loss of functional skills (self-care, toileting
etc.). Onset or increase of previously present autistic characteristics were reported in three
people with DS although some studies had excluded patients with co-morbid ASD [3,12].
Another symptom of particular note is weight loss, and in some cases the onset of what
was described as anorexia nervosa was reported. Weight loss and poor appetite are not
generally common in people with DS.
With four of the symptoms listed in Figure 2 it was possible to determine the severity
based on the vocabulary used to describe the symptoms. Reviewer determined categorisa-
tion of severity of symptoms was made based on descriptions given in the case studies,
shown in Table 3. Figure 3 shows the prevalence of the moderate and severe symptoms
identified in the case study data (Group A patients). It was not possible to complete this
analysis in the cohort studies (Group B) due to the grouping of many of symptoms together
which was not consistent across studies.
Table 3. Descriptive terminology used in articles reviewed. Four of the symptoms identified from
the case study data (Group A patients) were able to be analysed. Reviewer determined categorisation
of “moderate” or “severe” impact.











Weight loss Weight lossAppetite loss Anorexia nervosa
Slowing of movement SlownessSlow movement
Immobility
Becoming bedridden
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of their previously acquired language abilities. Sleep impairment was also more likely to
be severe than moderate.
A second area of analysis sought to identify patterns of symptom co-presentation in
those people with DS in the case studies (Group A). Patterns identified for this are shown
in Appendix B. Sleep disorder, deterioration in language, and becoming withdrawn and
disinterested were the symptoms that, if present, were associated with the full range of
symptomatology, rates of co-morbidity with other symptom clusters in most cases being
above 50%. In contrast, obsessive compulsive behaviours, fatigue, and abnormal blinking
and gaze are associated with co-morbidity rates with other symptoms of well under 50%.
What cannot be determined is whether such observations are a manifestation of where
the various patients were in the time course of the regression and/or whether this is a
manifestation of the maximum level of severity overall. The fact that sleep disturbance is
one of the reported early symptoms perhaps indicates that the early pathophysiology of
IDRS involves the hypothalamus. However, such pathophysiology would need to extend
beyond the hypothalamic and limbic systems to account for the onset of motor symptoms.
Mapping the course of symptom development and ultimately recovery through a longitu-
dinal study would provide valuable information, both in terms of clinical management but
also inform as to the likely underlying pathophysiological course. This analysis was not
possible for the cohort studies as there was no indication as to which participants expressed
multiple symptoms. As outlined in Table 3, symptoms reported include both their severe
and moderate forms.
4.4. Events Preceding Regression
Records of life events occurring prior to the onset of regression were often referred
to as “triggers” or “events” in the articles reviewed. The term “trigger” implies a causal
effect for which we cannot be certain, in fact, it is likely that many more people with Down
syndrome experience these same life events and do not develop IRDS. Among the articles
reviewed this information was recorded for a total of 93 patients. Data were collected from
the reviewed studies where reports of the same life event preceding a regressive episode
was evident in >1 patient. Figure 4 shows the number of patients identified as experiencing
such an event close to the time of their regressive episode onset.
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Figure 4 shows that “transition/change in environment” was the most commonly
reported life event that occurred around the time of an individual regressive episode.
Twelve of the 44 patients where this was suggested as a potential preceding event also
included additional information regarding the circumstances. Seven cases suggested there
was an association between graduation or leaving high school and the onset of a regressive
period (see Figure 5).
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pocampus (1), para hippocampal sulcus verticalisation (1), cerebellar hypotrophy (1) and 
cortical and cerebellar hypotrophy (1). Brain abnormalities were also reported using MRI 
neuroimaging in a single case study of a 19-year-old man with DS, however the nature of 
the abnormalities were not commented on further [15]. Of 11 EEGs conducted, all patients 
were reported as having normal EEG activity and from 23 polysomnography tests, two 
patients were reported as having abnormal findings, no further details were given. Addi-
tional brain abnormalities recorded included calcification of the pallidum, pineal body 
and habenular commissure, as well as low signal intensity in the pallidum and high signal 
intensity in the pyramidal tract and crossing of the superior cerebellar peduncles. Due to 
the absence of a comparison group or other studies to support these findings, it is not 
possible to determine from these results the significance with respect to IRDS. 
4.6. Medications, Interventions and Outcomes 
An important aim of this review was to give insight into the types of treatments and 
interventions used for this condition. As there are no treatment trials or controlled trials 
in this area, we have compiled a list of the medications and interventions reported across 
all the articles and the recorded outcome for the individual with DS. These details can be 
Environmental change/transistion as a potential trigger event 
for regressive episodes in DS
Graduation or leaving school Moving home
Flood in home Seperation from parents
Sibling moving home
Fi r . Breakdown of th environmental or transitional event circumstances that may have
preceded a regressive episode (n = 12).
4.5. rain bnor alities
rticles that rovi e brain-i aging data for the participants with DS were limited.
e ajority re orte o ab or alities sing brain RI [15,17,19] or EEGs [15,19]. MRI
ata in one case st y sho e hat ere re orted as senile changes in the five people
it S for o t ey a i agi g ata, i cl ing ische ic changes in the cerebral
hite atter, hi oca al atro hy an basal ganglia calcification [12]. Mircher et al. [18]
rovi e the ost substantial brain imaging data, with records of 15 people with DS
who underwent structural MRI. Eleven were reported as having normal brain structure,
while the remaining four showed indications of abnormal brain structure, specifically,
thin hi pocam us (1), para hi pocampal sulcus verticalisation (1), cerebellar hypotrophy
(1) and cortical and cerebellar hypotrophy (1). Brain abnormalities were also reported
using MRI neuroimaging in a single case study of a 19-year-old man with DS, however the
nature of the abnormalities were not commented on further [15]. Of 11 EEGs conducted, all
patients were reported as having normal EEG activity and from 23 polysomnography tests,
two patients were reported as having abnormal findings, no further details were given.
Additional brain abnormalities recorded included calcification of the pallidum, pineal body
and habenular co issure, as ell as lo signal intensity in the pallidum and high signal
intensity in the pyra idal tract and crossing of the superior cerebellar peduncles. Due
to the absence of a comparison group or other studies to support these findings, it is not
possible to deter ine fro these results the significance ith respect to IRDS.
4.6. Medications, Interventions and Outcomes
An important aim of this review was to give insight into the types of treatments and
interventions used for this condition. As there are no treatment trials or controlled trials
in this area, we have compiled a list of the medications and interventions reported across
all the articles and the recorded outcome for the individual with DS. These details can
be seen in Appendix A. In the absence of controlled trials, it is not possible to provide a
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review on the efficacy of a treatment, however it is interesting to note the wide variation
of medications administered, the majority of which were given for different durations, at
different dosages and alongside different additional medications. Thus, it is impossible
to do any direct comparisons but it is important to be aware of the variety in the current
interventions used.
Treatments that were administered to more than one person with DS have been
recorded in terms of the response rate that was observed, either a positive, negative or no
response (see Figure 6). It should be noted that in almost none of these examples were
drugs/treatments the sole intervention, there was usually a combination of treatments that
is not reflected in Figure 6; dosages and treatment lengths were also not recorded. For the
purpose of this analysis, each treatment and response is entered as its own entity.
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Anti-depressants and anti-psychotics were the most frequently used medications.
Anti-depressants were reported as having had almost equal positive and negative effects
with slightly fewer people with DS showing no changes after the medication. Of all the
anti-depressants administered, clomipramine was the only one that was reported as result-
ing in improvement in all four people with DS it was given to, with one complete recovery.
In this case 150mg clomipramine was administered once per day for six weeks. One
hundred and fifty milligrams of desipramine had been administered previously but found
to be ineffective. Electro-convulsive therapy (ECT) was found to be very effective. Of the
10 patients receiving this treatment four were reported to have made a full recovery [15,18],
and a further four made significant recoveries to more than 80% of their baseline function-
ing [20]. Other patients showed complete resolution of some behaviours [19] and a “robust
response” respectively [15]. There was, however, a high occurrence of discontinuation
of ECT treatment, frequently resulting in relapse. Many patients receiving ECT had a
preponderance of catatonia features [15,19,20], which may explain its effectiveness. Based
on the wide variety of treatments employed and the large number that exhibited either
no response or a negative response, clearly there is no consensus among practitioners
regarding best treatment practice and there is a great need for improvement, both in our
understanding of regression in people with DS and in the potential treatments.
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4.7. Prognosis
Overall, the majority of people with DS made some level of recovery from their
regressive episode (Figure 7). Despite the range of different treatments used the majority
appear, on the basis of clinicians’ reports, to have had mostly beneficial effects. Most
intriguing is the finding that all patients treated with ECT showed a positive response.
However, it is noteworthy and of concern that 66% of patients made only a partial recovery
and did not return to their baseline functioning. Of those making a good recovery and
even those returning to near pre-regression levels it was often reported that whilst most
symptoms had been resolved, a specific behaviour or symptom remained. In some of
these cases the remaining symptom(s) was very detrimental to daily life, such as persistent
insomnia or unresolved mutism. Only eight people with DS (20%) made a full recovery to
their baseline functioning, whilst two made no improvements and a further two withdrew
from their treatment program and were not followed up.
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5. iscussion
e undertook a systematic review to increase our understanding of the nature of early
regression in adults and adolescents with DS. The standalone term “regression” was used
for this systematic review in order to capture as many relevant articles as possible. Based
on the overwhelming number of articles referencing only a form of statistical regression
this is not a method that should be recommended. Out of 1938 articles identified in the
search only a small number of independent articles including observational case and
cohort studies with a total of 186 people with DS were identified. Within these articles,
39 people with DS were presented as case studies/vignettes, providing qualitative details
about the nature of their regression, symptoms, treatments and prognosis. Contrary to
previous observations reporting a clear preponderance of females [8], males represented
just under half of the population identified in this review (46.2%). Previous reports have
identified the impact of IRDS [23], however, there are many differing opinions on the
interpretation and classification of IRDS, including the diagnoses of reactive depressive
illness [14], and catatonia [15].
We identified the use of a total of 17 different descriptive terms to label this condition
within the title, abstract and keywords in 13 articles. This review is by no means the first to
notice the issues surrounding the description of this condition. Worley et al. [22] initiated
the use of the term DSDD in their paper detailing autistic like regression in young children
with DS. Of the articles included in this review that have been published since, few have
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continued with the use of DSDD [8,22]. However, other papers have referenced Worley
et al., and repeated the concern of the lack of a unified term [16,18].
In this review, we grouped the symptoms that were noted within the cases studies
(Group A) and those seen in the cohort studies (Group B). In the absence of a population-
based study an estimate of the age-specific prevalence of IRDS was not possible. However,
with the case study data (Group A) the description of symptoms was detailed and quali-
tative in nature thus allowing further insight into the severity of the symptoms. For the
purpose of this review, observations concerning the 10 most predominant symptoms from
Group A were identified, and then supplemented with data from Group B, the cohort
studies. There were many individual cases of very specific changes and skill loss that were
not necessarily representative of others with the condition, therefore symptoms noted in
less than 10% of all cases were not reported in this analysis. Our priority was to identify the
symptoms that were most commonly seen, the severity of those symptoms, and whether
or not they were associated with the presence of other symptoms. Determining severity
was especially problematic in this review as in the absence of baseline data it was difficult
to quantify skill loss. In the case studies there was some additional information given
about an individual’s prior behaviour and capabilities thus enabling some judgment about
severity, however for consistency, the descriptive words used by the article were used to
group symptoms.
In contrast to the Rosso et al. review [8], our review found that sleep disturbance was
the most significant clinical feature. As in the other review, language skills decline and
changes in behaviour, specifically becoming disinterested and withdrawn, were frequent.
These latter symptoms were evident in around 50% of both Group A and B participants.
For Group A we were able to cross-reference symptoms in an effort to establish patterns
and high rates of symptom co-morbidity. We found that deterioration in sleep and speech
was highly associated with almost all other symptoms, including slowness, weight loss
and depression. Other associations that were seen less frequently included catatonia with
skill loss, weight loss with increased slowness, and aggression with hallucinations.
Across the case studies that were reviewed there was a considerable difference in the
type and amount of detail given. The majority of case studies reported in a narrative style
without particular consistency in language or inclusion. This style provided the greatest
detail and in-depth analysis. Studies where narratives were not used were slightly more
problematic. For example, Akahoshi et al. [12] provided a table for their case reports with
minimal qualitative data. It was considered that the subtleties of the symptoms may have
been lost in an attempt to fit the criteria into pre-set categories. Eleven of the cases were
described as showing signs of abulia (11) or hyperboulia (1), however, this symptom was
not identified in any other case report narrative reviewed. Eight of these patients were
also diagnosed with insomnia, the most severe of the sleep disorders reported and none
with more moderate impairments. Whilst this may be a true reflection of the patients’
symptoms it is also possible that a reduced number of descriptors were decided on to fit
pre-determined categories. The unique reporting methods were almost more in line with
that of the cohort data. A limitation we are aware of is the impact that such results can
have on review data, particularly in small samples such as these.
Severity of symptoms was deduced for participants (both Groups A and B) based
on the language used to describe or classify the symptoms. It was clear that within
the descriptions of sleep disorders and language decline, the presence of more severe
symptoms significantly outweighed the more moderate symptoms. For these categories,
this equates to more patients suffering from insomnia rather than disturbed sleep, and
more patients described as experiencing mutism in comparison to less severe decline in
language skills. Weight loss was also of interest as equal numbers of people with DS were
reported as having suffered from loss of weight/appetite or a diagnosis of anorexia nervosa.
Information was not given as to the exact nature of the symptoms that led to a diagnosis
of anorexia nervosa, for example the nature and extent of body dissatisfaction, and it is
likely that a diagnosis of anorexia nervosa in someone with DS may be difficult to make
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reliably. Interestingly, in the general DS population weight loss is not often reported. More
typically the opposite, over-eating and weight gain is considered problematic, therefore,
relatively high numbers of people with DS experiencing weight loss and receiving the
diagnosis of anorexia nervosa may be an important indicator of symptomatology that is
specific to this condition. The reasons behind appetite loss and weight change were not
given in the articles reviewed, however, there is a strong co-presentation of disinterest and
withdrawal in those whose weight changed, including four of those who were reported to
have developed anorexia nervosa. Clinical features of IRDS must be identified if there are
hopes of raising awareness of this condition, Table 4 presents the profile of IRDS.
Table 4. Proposed clinical features of IRDS.
Core Symptoms and Signs Potential Triggers for Regression Exclusions
New onset poor sleep Transitions Autism spectrum disorder presents in 5 yearsand above
Change in language output (e.g., changes in an individual’shome/school/college routine)
Medical causes (incl. thyroid dysfunction and
other conditions with autoimmune aetiology)
Abulia, withdrawal, disinterest,
personality changes Life events New onset sensory impairment
Mood changes, loss of appetite and
weight loss Stressors Age-related decrease in activity
Motor features–catatonia, stereotypies,
extra-pyramidal signs Other mental illness (e.g., depression)
Loss of skills (adaptive functioning) Unlikely over the age of 40 years (dementia ispossible)
On the surface, the statistics for recovery rate appear very positive. In our review only
two individuals from Group A were reported as having made no improvement. However,
66% of patients made only a “partial recovery” (n = 26). This encompassed everything from
slight improvement to near baseline functioning. Although making a recovery to “near
baseline” may appear positive, in many cases one or more severe symptoms remained,
including insomnia and mutism. In the case studies only eight people with DS recovered
their full baseline abilities and functioning level after experiencing a regressive episode.
The time course of IRDS remains uncertain in the absence of systematic longitudinal studies
and it is also unknown whether there is a time point in the course of IRDS after which
further recovery is unlikely.
Overall, the treatments used had varying results. Anti-depressants (including;
clomipramine, bupropion, trazodone, fluvoxamine, desipramine, amitriptyline, nortripty-
line and citalopram) were the most commonly administered drug type, the effects of which
were almost equal between a positive, negative and no response. Similar numbers of posi-
tive and negative respondents were seen from the use of anti-anxiety drugs (mexazolam,
bromazempam, benzodiazepines, lorazepam). Clomipramine exhibited a positive response
in all people with DS it was given to, whilst ECT and immunotherapy appeared to have
the most positive outcomes, with all patients exhibiting a positive response, although in
each treatment the numbers were small (10 and 5 cases, respectively). Anti-psychotic medi-
cations (clozapine, levomepromazine, haloperidol, olanzapine, aripiprazole, ziprasidone
and thiothixene) resulted in more positive responders than negative or no response. Of
significant concern, both clinically and in terms of drawing any conclusions, is that in very
few cases was a single treatment given independently and across the studies the length
of administration and dosage varied, as were the other treatments that were alongside.
For the purposes of this analysis, each intervention has been taken as an independent
entity. Whilst this is far from ideal, it is impossible to accurately record response to a single
treatment when multiple are prescribed in conjunction. There were no controlled treatment
trials among the studies reviewed and in the absence of such trials it is impossible to be
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certain whether or not reported improvements following treatment are a manifestation of a
treatment effect or just an indication of the natural history of IRDS in that individual.
Many of the symptoms presenting in IRDS are also seen in other conditions, such as
depression and anxiety, or are seen in response to stress. These conditions may present
atypically in people with DS [13], including the loss of functional skills, sleep impairment
and reduced language [24]. In several studies, it was noted that people with DS were not
experiencing depression prior to the episode, and many individuals were unresponsive to
psychotropic drugs. Furthermore, some of the behaviours and changes, such as mutism,
were never reversed despite making an otherwise complete recovery. This extent of
persistent loss is not commonly seen in pure mood disorders.
A striking feature of IRDS is the age of onset, which is at an age when brain develop-
ment is in its final stages and still susceptible to being disturbed. This age of risk for IRDS
is later than that of classical autistic regression, or that observed in other rare neurodevel-
opmental disorders, and earlier than would be expected for dementia. Furthermore, the
majority of studies have not reported abnormal imaging (MRI) or encephalographic (EEG)
findings [15,17,19]. Other data showed senile changes in the five people with DS that re-
ceived an MRI scan; however, there was no comparison or longitudinal data available [12].
Although routine medical screening (such as for thyroid disease, coeliac disease and vita-
min D deficiency) undertaken in people with DS presenting with possible regression may
be abnormal, it is unlikely such abnormalities are causative [4]. However, treatment of
co-occurring medical conditions may improve prognosis.
The presentation of IRDS has been likened to that of dementia. Although the age of
onset of dementia in people with DS is early compared to the general population it is still
considerably later than the typical age of onset of IRDS. Myers and Pueschel [10] included
a case study of a 44-year-old person with DS, excluded from this review due to our age
inclusion criteria, who exhibited very similar symptoms to that of the younger participant,
but the psychiatric diagnosis was AD. The major differences between the type of regression
discussed in this review and dementia is the age of onset and, most crucially, that patients
often show some recover from IRDS. No recovery is seen in those diagnosed with AD.
Many other diagnoses have been considered to explain this early regression, including
psychotic illness, catatonia, mania, depression and anxiety. Autoimmune encephalopa-
thy and mitochondrial dysfunction have been considered as possible underlying mecha-
nisms [25,26]. Immune abnormalities are typical in children with DS [27]) and may be of
aetiological significance. Interestingly one of the most effective treatments reported in this
review were drugs impacting on the immune system, where all but one individual (who
discontinued their use due to negative side effects) saw positive results, including one full
recovery, and full recovery with the exception of persistent insomnia.
At present the underlying cause(s) of IRDS and why it appears to be specific to people
with DS are unknown. One key question is whether we know enough about IRDS at
present to argue that IRDS is a specific condition with a common, but as yet unknown,
aetiology. Rosso et al. [8] argue that, as the cause(s) of IRDS is unknown, a full clinical
work up in all cases of young people with DS who report such changes is required to
identify possible explanatory and potentially different diagnoses. If, on the other hand, all
clinically diagnosed cases of IRDS are in fact considered to have a common cause a further
question is whether that is best explained as a consequence of the atypical presentation
of a known co-morbid condition (e.g., catatonia), which occurs in other populations but
happens to be more common in people with DS; or whether IRDS is a condition that has
an aetiology that is unique and specific to DS, and ultimately can be linked back to the
presence of trisomy 21. The paper by Miles et al. [20] interestingly reported on seven
patients with DS who had developed regression and the authors proposed that in each
case this regression was due to catatonia. Using the Bush–Francis Catatonia Rating Scale
and demonstrating a positive response to intravenous lorazepam they argued that this was
true catatonia. They also reported a good response to ECT and other treatments although
recovery was often not maintained. Such observations would suggest that regression is
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due to a condition (in this case catatonia) that can affect anyone, but that people with
DS at a specific age are particularly vulnerable. However, although people with other
neurodevelopmental syndromes may have syndrome specific neuropsychiatric risks, to
our knowledge similar episodes of regression in the same age range are rare in people
with other neurodevelopmental syndromes. This is more in support of the hypothesis
that IRDS is a DS specific condition. An exception to this is cases of regression in people
with SHANK3 mutations (Phelan–McDermid syndrome), reported in two papers [28,29].
For people with Prader-Willi Syndrome, particularly those with the maternal uniparental
disomy form, a regressive type of clinical deterioration can be seen in the same age group
as IRDS but the symptomatology is much more obviously that of a psychotic illness [30].
Although there are some differences in symptom prevalence [8] the symptomatology that is
described in both reviews would appear to separate IRDS from other potential aetiologies,
such as affective disorder. However, such uncertainties as those described above are clearly
hindering a rational approach to treatment development.
It is unknown whether there are specific risk markers and biomarkers that are either an
indicator of vulnerability to IRDS or can map to the presence and severity of the IRDS and
are potential indicators for underlying causative mechanisms. These need to be studied and
markers identified and then followed over time. Whether there is a relationship between
the risk for regression and the later risk of dementia is unknown and specifically whether
there are genetic markers that affect the vulnerability to dementia (e.g., ApoE genotype
and soluble TREM-2) are also associated with regression. And whether biomarkers of other
potential mechanisms (e.g., myelodysplasia, leukopenia, macrocytosis), and inflammatory
markers (e.g., inflammation related factors, cytokines) are important and need further
investigation. Many of these markers have been identified as being associated with major
psychiatric disorders.
A striking observation is the potential role of transitional life events and changes in
environment as a potential trigger for regression. IRDS may be best considered as a condi-
tion triggered by stress and occurring in people with DS who have some additional genetic
or acquired vulnerability (low resilience). Alternatively, IRDS is due to the occurrence of an
acquired condition that results in a direct, and initially adaptive response in the brain to the
insult and subsequently in a temporary and adverse effect on brain function. For example,
an acquired insult may lead to the development of an inflammatory response in the brain
resulting in an encephalopathy that subsequently completely or partially resolves.
Limitations
There are several limitations with this review article that have mostly been discussed
in the course of this review. First, the search strategy used to capture relevant articles vastly
over-included studies and returned a huge number of results that were irrelevant. The
difficulty with this search centred on the labelling words used to describe this condition,
and that there is not a unified term. Our compromise, after trialling many search strategies,
was to include the word “regression” without additional restrictions. While this returned
the best results in so far as the few relevant articles, there were also a plethora of studies ref-
erencing only statistical regression that needed to be manually eliminated. It is recognised
that it is not good practice to have such a large difference between the number of articles
sourced and those retained, it was deemed necessary based on the confusion seen in the
terminology used for this condition. Although the methodology was time consuming and
over-inclusive, using the particular search criteria selected we are confident that the correct
papers have been identified and included.
The articles included in this paper were all observational studies, both case and cohort
studies. The positive aspects of observational data are that records are usually qualitative
and highly descriptive, allowing for cross-referencing between symptoms to be explored
and person-by-person outcomes evaluated based on interventions. The negatives are
that the quality of evidence is low. Cochrane’s levels of evidence quality [31] describe
randomised controlled trials as giving the highest quality of evidence and observational
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studies amongst the lowest. As such any conclusions drawn from the studies must be very
cautiously considered. It is our hope that further insight and raising awareness will lead to
a greater interest in research of this condition and promote controlled trials in the future.
Despite these limitations this review has provided insight into an under-researched
condition with significant impacts on people with DS and their families. This review
intends to bring to light a serious condition affecting a minority of young adults and
adolescents, many of whom never recover their baseline functioning. It is important that
we now seek to focus on prevention and treatment of this condition.
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Appendix A
Table A1. Table showing the range of treatments administered across all papers on an individual basis alongside re-
ported outcome.
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Clozapine 1 1“85% return to baseline”









Thiothixine 2 1“Complete recovery”
1
“No change”
Amitriptyline 1 1“Complete recovery”
Nortriptyline 1 1“Unsuccessful”
Clonazepam 2 1“Partial improvement”
1
“Unsuccessful”
Ethosuximide 1 1“No effect”
Lidexamfetamine 1 1“Worsening”
SSRI citalopram 1 1“Worsening”
Amiloride 1 1“Improvement”
Lamotrigine 1 1“No effect”
Antipsychotic treatment 1 1“Good response”
Note: dosages and additional medications/treatments are not reported.
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Sleep 0 10 71 9 64 8 57 10 83 9 82 7 64 7 70 6 60 6 75 6 86 2 33 5 83 4 80 2 50
Language 10 45 0 3 21 7 50 4 33 7 64 6 55 2 20 6 60 6 75 4 57 2 33 1 17 0 0 2 50
Withdrawal and disinterest 9 41 3 21 0 6 43 5 42 5 45 4 36 8 80 2 20 0 0 2 29 3 50 4 67 3 60 0 0
Slowness and immobility 8 36 7 50 6 43 0 7 58 5 45 4 36 2 20 4 40 5 63 2 29 1 17 3 50 2 40 4 100
Weight loss and anorexia 10 45 4 29 5 36 7 50 0 3 3 4 36 2 20 2 20 2 25 2 29 1 17 1 17 4 80 2 50
Depression 9 41 7 50 5 36 5 36 3 25 0 4 36 0 0 2 20 6 75 2 29 1 17 0 0 0 0 2 50
Hallucinations 7 32 6 43 4 29 4 29 4 33 4 36 0 0 0 4 40 0 0 2 29 0 0 0 0 0 0 3 75
Abulia 7 32 2 14 8 57 2 14 2 17 4 36 0 0 0 0 0 2 25 2 29 0 0 0 0 0 0 3 75
Skill loss 6 27 6 43 2 14 4 29 2 17 2 18 6 55 2 20 0 2 25 0 0 1 17 0 0 2 40 0 0
Catatonia 6 27 6 43 0 0 5 36 2 17 2 18 0 0 2 20 6 60 0 0 0 0 0 0 0 3 60 0 0
Aggression 6 27 4 29 2 14 2 14 2 17 2 18 2 18 2 20 2 20 0 0 0 2 33 0 0 1 20 0 0
Irritability 2 9 2 14 3 21 1 7 1 8 1 9 0 0 3 30 1 10 2 25 2 29 0 2 33 0 0 2 50
Obsessive compulsions 5 23 1 7 4 29 3 21 1 8 0 0 0 0 4 40 0 0 0 0 4 57 2 33 0 0 0 0 0
Fatigue 4 18 0 0 3 21 2 14 4 33 0 0 0 0 0 0 0 0 0 0 2 29 2 33 0 0 0 1 25
Abnormal blinking and gaze 2 9 2 14 0 0 4 29 2 17 2 18 3 27 1 10 2 20 1 13 0 0 0 0 0 0 1 20 0
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